CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates

CorMedix (CRMD) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of$ 0.26. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.85%. A quarter ago, it was expected that this pharmaceutical and medical device company would post a loss of$ 0.27 per share when it actually produced a loss of $0.25, delivering a surprise of 7.41%. Over the last four quarter ...